Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – America's chronic disease burden has reached $4.9 trillion in annual healthcare expenditures, driven by an aging population that will see Medicare spending surge from 6.6% to 9.2% of GDP by 2050[1]. Meanwhile, the FDA has streamlined obesity drug development pathways[2] while gene therapy approvals accelerated in August 2025[3], as specialty pharmacy networks expand to deliver advanced treatments directly to patients[4]. This convergence is creating outsized opportunities for early-positioned companies developing next-generation therapies across metabolic diseases, oncology, and rare genetic conditions: Avant Technologies, Inc. (OTCQB: AVAI), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Viking Therapeutics, Inc. (NASDAQ: VKTX), Tenaya Therapeutics, Inc. (NASDAQ: TNYA), and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).
Industry analysts project the global immunology market will exceed $250 billion by 2032[5], while biotechs are increasingly securing collaborative partnerships that provide shared risk capital and streamlined regulatory pathways[6]. Recent payer coverage expansions and specialty pharmacy investments, including Cigna's $3.5 billion commitment to Shields Health in September 2025, signal that the infrastructure and reimbursement landscape is finally aligned to support innovative therapies at scale[7].
Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic pivot into the high-growth longevity biotechnology sector through a transformative joint venture with Singapore-based Austrianova (SGAustria Pte. Ltd.), establishing Klothonova, Inc. as a 50/50 partnership focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells. This agreement positions Avant at the forefront of anti-aging therapeutics by leveraging Austrianova's proprietary cell-encapsulation technology and decades of expertise in cell biology and GMP-grade manufacturing.
The joint venture targets multiple lucrative therapeutic areas including Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions through innovative treatments based on Klotho protein overexpression. Austrianova brings substantial intellectual property backed by over 50 peer-reviewed publications and established partnerships with global pharmaceutical companies, while Avant provides capital and operational resources to accelerate Klothonova's development pipeline.
"We are thrilled to partner with Austrianova, whose world-class expertise in cell encapsulation and GMP manufacturing complements our vision for advancing transformative healthcare solutions," said Chris Winter, CEO at Avant Technologies. "Klothonova represents a significant step toward addressing some of the most pressing medical challenges of our time."
The scientific foundation appears compelling based on extensive research demonstrating Klotho's therapeutic potential. Studies show that higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lowest Klotho levels had 31% higher mortality rates than those with higher levels. Critically, natural Klotho levels drop by 50% after age 40, creating substantial therapeutic opportunities for intervention.
Klotho, discovered in 1997 and primarily produced in kidneys and brain tissue, functions as a crucial "longevity protein" that modulates aging processes while affecting brain, heart, kidneys, and immune function simultaneously. Research has linked Klotho to improved cognitive function, cardiovascular health, and kidney function, with demonstrated potential in combating age-related diseases.
"This joint venture with Avant Technologies allows us to combine our proprietary technologies with Avant's resources to accelerate the development of Klotho-based therapies," added Brian Salmons, CEO at Austrianova. "We are excited about the potential to improve patient outcomes and promote healthier, longer lives."
The market opportunity appears substantial across multiple therapeutic areas. The global Alzheimer's disease market is projected to reach $32.8 billion by 2033, while cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. Austrianova's proven Cell-in-a-Box® technology with 30+ years of development enables sustained, controlled delivery of Klotho-producing cells through established GMP manufacturing capabilities.
This strategic transformation positions Avant within the rapidly expanding longevity biotechnology sector, with Klothonova's exclusive licensing arrangements and equal ownership structure creating multiple potential value creation pathways as Klotho-based treatments advance toward clinical validation and commercialization across global markets.
CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has expanded patient access for Amtagvi through a specialty pharmacy partnership with InspiroGene by McKesson. Amtagvi represents the first FDA-approved tumor-infiltrating lymphocyte therapy for solid tumors, specifically targeting patients with advanced melanoma after immune checkpoint inhibitor and targeted therapy. The personalized treatment harnesses patients' own T cells, which are extracted from tumors, expanded, and re-infused to fight cancer.
"We chose InspiroGene by McKesson to pioneer the AMTAGVI specialty pharmacy option due to their offerings and commitment to cell and gene therapy patient access," said Dan Kirby, Chief Commercial Officer at Iovance Biotherapeutics, Inc. "We believe that InspiroGene will play a critical role in ensuring seamless delivery and coordination of Amtagvi to authorized treatment centers. The addition of the specialty pharmacy channel marks a significant step forward in Iovance's objective to bring innovative, life-extending therapies to more patients, more efficiently."
The partnership enables treatment centers to access the product through their preferred channel while reducing administrative burdens for providers. Iovance continues expanding its TIL platform across multiple solid tumor indications as the pioneer in this transformational cancer treatment approach.
Viking Therapeutics, Inc. (NASDAQ: VKTX) delivered positive results from its Phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation, achieving up to 12.2% mean weight loss after 13 weeks compared to 1.3% for placebo. The dual GLP-1/GIP receptor agonist demonstrated statistically significant reductions across all primary and secondary endpoints with 80% of patients in the highest dose group achieving at least 10% weight loss. VK2735 showed progressive weight loss with no plateau observed at 13 weeks and 99% of gastrointestinal adverse events were mild or moderate.
"We are excited to report the top-line Phase 2 study results for the once-daily oral tablet of VK2735," said Brian Lian, CEO of Viking Therapeutics. "As in prior studies we observed a clear dose response and impressive weight loss across the 13-week treatment period. The progressive nature of the weight loss curves suggests the potential for further improvement with longer dosing periods."
The company is evaluating both oral and subcutaneous formulations of VK2735, with two Phase 3 obesity trials (VANQUISH-1 and VANQUISH-2) ongoing for the injectable version. An exploratory maintenance dosing cohort demonstrated sustained weight loss when patients transitioned from 90mg to 30mg daily doses.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) presented interim data from its MyClimb natural history study, the largest noninterventional study of pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy. The study enrolled 213 participants from 27 centers across the US, Canada, Spain and UK, with 93% having the nonobstructive form of HCM for which no approved therapeutics exist. Key findings revealed distinct risk profiles based on genetic inheritance patterns, with homozygous patients experiencing nearly universal death or heart transplant before age one.
"Data obtained from MyClimb offer actionable information for predicting those severe MYBPC3-associated HCM pediatric patients who may be at higher risk of death or severe complications, such as life-threatening ventricular arrhythmias, cardiovascular-related hospitalizations, heart failure, sudden cardiac arrest, and/or heart transplant," said Whit Tingley, Chief Medical Officer at Tenaya Therapeutics. "Among the new observations, we believe certain genetic profiles or higher left ventricular mass index can identify those children who are at substantially greater risk of serious potential complications, relatively rapid progression and poor long-term outcomes."
The study identified Left Ventricular Mass Index as a significant predictor of risk that may serve as a surrogate marker for evaluating gene therapy effectiveness in future pivotal studies. Tenaya is developing TN-201 gene therapy for MYBPC3-associated HCM, with longer-term follow-up data from Cohort 1 and initial Cohort 2 data expected in Q4 2025.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) provided an update on its submission of additional clinical data to the FDA supporting Zynquista for Type 1 diabetes treatment. The company submitted data from three ongoing investigator-sponsored studies conducted by Steno Diabetes Center, Joslin Diabetes Center, and University of Dundee to address the December 2024 complete response letter citing diabetic ketoacidosis concerns.
The FDA now requires additional time to review this data and expects to provide feedback from the Type D meeting in Q4 rather than the previously anticipated end of September timeline.
The company seeks alignment on a reasonable path forward for the Zynquista New Drug Application resubmission following the regulatory feedback. Zynquista, an oral SGLT1/SGLT2 inhibitor, has been studied in approximately 20,000 patients across multiple conditions including heart failure, diabetes, and chronic kidney disease.
Sources: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/
CONTACT:
Baystreet.ca
cs@baystreet.ca
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
--
SOURCES CITED
1. https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html
2. https://www.medpace.com/blog/new-fda-guidance-developing-drugs-and-biological-products-for-weight-reduction/
3. https://www.cgtlive.com/view/fda-activity-recap-august-papillomatosis-gene-therapy-approval-eli-cel-labelling-update
4. https://accessmarketintell.com/2025/09/02/specialty-pharmacy-news-roundup-august-2025/
5. https://liberigroup.com/biotech-partnerships-in-2025-trends-and-opportunities/
6. https://www.biospectrumasia.com/opinion/54/26575/collaborative-rd-partnerships-shaping-the-future-of-biopharma.html
7. https://www.modernhealthcare.com/insurance/mh-cigna-shield-health-investment-specialty-pharmacy/
Related Stories
